Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

Yao, 2008, One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States, J Clin Oncol, 26, 3063, 10.1200/JCO.2007.15.4377

Choti, 2012, Prevalence of functional tumors in neuroendocrine carcinoma: an analysis from the NCCN NET database, J Clin Oncol, 30, 4126, 10.1200/jco.2012.30.15_suppl.4126

Yao, 2012, Optimising therapeutic options for patients with advanced pancreatic neuroendocrine tumours, Eur Oncol Haematol, 8, 217, 10.17925/EOH.2012.08.4.217

Rinke, 2009, Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group, J Clin Oncol, 27, 4656, 10.1200/JCO.2009.22.8510

Caplin, 2014, Lanreotide in metastatic enteropancreatic neuroendocrine tumors, N Engl J Med, 371, 224, 10.1056/NEJMoa1316158

Yao, 2011, Everolimus for advanced pancreatic neuroendocrine tumors, N Engl J Med, 364, 514, 10.1056/NEJMoa1009290

Raymond, 2011, Sunitinib malate for the treatment of pancreatic neuroendocrine tumors, N Engl J Med, 364, 501, 10.1056/NEJMoa1003825

Blumenthal, 2012, FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors, Oncologist, 17, 1108, 10.1634/theoncologist.2012-0044

Fazio, 2013, Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study, Chest, 143, 955, 10.1378/chest.12-1108

Pavel, 2012, RAMSETE: a single-arm, multicenter, single-stage phase II trial of RAD001 (everolimus) in advanced and metastatic silent neuro-endocrine tumours in Europe, J Clin Oncol, 30, 4122, 10.1200/jco.2012.30.15_suppl.4122

Bajetta, 2014, Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study, Cancer, 120, 2457, 10.1002/cncr.28726

Pavel, 2011, Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study, Lancet, 378, 2005, 10.1016/S0140-6736(11)61742-X

Rindi, 2010, Nomenclature and classification of neuroendocrine neoplasm of the digestive system, 13

Klimstra, 2010, The pathologic classification of neuroendocrine tumors, Pancreas, 39, 707, 10.1097/MPA.0b013e3181ec124e

Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205

Fernandez-Cuesta, 2014, Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids, Nat Commun, 5, 3518, 10.1038/ncomms4518

Francis, 2013, Somatic mutation of CDKN1B in small intestine neuroendocrine tumors, Nat Genet, 45, 1483, 10.1038/ng.2821

Banck, 2013, The genomic landscape of small intestine neuroendocrine tumors, J Clin Invest, 123, 2502, 10.1172/JCI67963

Yao, 2008, Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study, J Clin Oncol, 26, 4311, 10.1200/JCO.2008.16.7858

Meric-Bernstam, 2012, PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors, Clin Cancer Res, 18, 1777, 10.1158/1078-0432.CCR-11-2123